Article Details
Retrieved on: 2021-10-05 18:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The commercial developer, Maryland-based ReveraGen BioPharma, has sponsored two open-label, dose-finding trials with vamorolone in boys with DMD who had not ...
Article found on: www.medpagetoday.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here